Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
Mobile:
Tel:
Fax: +86-571-57153510
URL: http://www.chinazerchem.com
Province/state: Zhejiang Province
City: Hangzhou City
Street: No 317,Jingling Road,Guali Town,Xiaoshan District
MaxCard:
CAS NO.379270-37-8
Tenofovir alafenamide (INN/USAN, formerly GS-7340) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent.
Gilead announced a phase 3 clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with cobicistat, emtricitabine and elvitegravir and developed a coformulation of the drug with cobicistat, emtricitabine and the protease inhibitor darunavir. In a 48 week study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (trade name Genvoya), the results showed the newer drug to be noninferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function. The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015. Genvoya is the first TAF-based regimen to receive approval.
Hangzhou ZeErRui Chemical Co., Ltd. is focused on customization, research and development and production of APIs and advanced intermediates, which can effectively compensate for the deficiencies of traditional CRO and CMO. Priority of high-tech barriers, high value-added, low pollution characteristics of the project, landing the project of innovative non patented route design, difficult process development and rapid industrialization. Starting from the advantages of combining technology research and stable production, Lead Biotech cooperated with domestic and foreign large pharmaceutical companies in the development of generic drugs and innovative drugs.
It also has hardware facilities and support teams that match the strength of R & D and production: With LCMS, HPLC and other perfect detection means, professional testing team and perfect quality control system; With a pilot base, a stable GMP standard production capacity, and a new GMP workshop is building; With regular financial, legal ERP system and professional sales and logistics team.